Conclusion: Rasagiline is an investigational selective and irreversible inhibitor of MAO-B that has demonstrated efficacy and safety for the treatment of PD. Whether rasagiline is associated with ...

is a new reversible selective monoamine oxidase B (MAO-B) inhibitor being studied for its potential in treating neurodegenerative diseases like Alzh The ongoing obesity Phase 2 trial is a ...

In patients receiving serotonergic medications in combination with an MAOI, there have been reports of serious and sometimes fatal reactions, including hyperthermia, rigidity, myoclonus ...

Rejection sensitive dysphoria is self-perceived shame and distress from rejections at work, school, online, or elsewhere.

There’s been no shortage of blockbuster deals as the J.P. Morgan Healthcare Conference kicked off Monday in San Francisco, and now Eli Lilly has joined the fray, setting down $1 billion up front for ...

This valuable study investigates how the proteins of the Cdv division system in Metallosphaera sedula archaea sequentially interact with curved membranes in vitro, extending our understanding of this ...

The global burden of anxiety- and depression-related disorders is on the rise. While multiple drugs have been developed to ...

After hours: January 16 at 6:47:09 PM EST Loading Chart for BF-B ...

U.S. value stocks are tallying their longest losing streak on record. Why they could see a comeback in 2025.